SCREENING AND DEVELOPMENT OF INHIBITORS AND ACTIVATORS FOR DEGRADATION OF ORNITHINE DECARBOXYLASE (ODC)

鸟氨酸脱羧酶(ODC)降解抑制剂和激活剂的筛选和开发

基本信息

  • 批准号:
    09680632
  • 负责人:
  • 金额:
    $ 1.54万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1997
  • 资助国家:
    日本
  • 起止时间:
    1997 至 1998
  • 项目状态:
    已结题

项目摘要

Ornithine decarboxylase (ODC) is a key enzyme in polyamine biosynthesis and the only known enzyme degraded by the 26S proteasome without ubiquitination. Reagents that could modify ODC degradation could help resolve the physiological importance of ODC degradation and analyze degradation mechanism of non-ubiquitinated substrates by the 26S proteasome. The aim of this study is screening and development of inhibitors and activators of ODC degradation. The following results were obtained by the present study. 1) Three inhibitory substances were isolated from broth of Actinimycetes. One was identified as Antimycin A (ID50 : O.1mg/ml). Chemical structures of other two substances were close to Julimycin-BII and Julichrom Ql, 4, respectively. Their activities were comparable to that of lactacystin. 2) Known antibiotics were screened, and Actinomycin D and Glioririn were found to inhibit ODC weakly. 3) A strong inhibitory activity was found in broth of a mold. It was separated to several related substances by reversed phase chromatography and IC50of some of them were lower than 1mug/ml. Their purification is under way. 4) Agmatine was found to accelerate ODC degradation by frameshift induction of antizyme. 5) Several amines or basic amino acids were found to affect the efficiency of frameshift induction of antizyme.
鸟氨酸脱羧酶(ODC)是多胺生物合成的关键酶,也是目前已知的唯一一种被26S蛋白酶体降解而没有泛素化的酶。能够修饰ODC降解的试剂有助于解决ODC降解的生理意义,并通过26S蛋白酶体分析非泛素化底物的降解机制。本研究的目的是筛选和开发ODC降解的抑制剂和激活剂。本研究取得了以下研究成果。1)从放线菌发酵液中分离得到3种抑菌物质。1例为抗霉素A(ID50:0.1 mg/ml)。另外两种物质的化学结构分别与Julimycin-BII和Julichrom QL,4相近。它们的活性与lactacystin的活性相当。2)对已知抗生素进行筛选,发现放线菌素D和格列瑞林对ODC的抑制作用较弱。3)霉菌发酵液具有较强的抑菌活性。用反相色谱分离出几种有关物质,IC50部分低于1µg/ml,目前正在进行分离纯化。4)胍丁胺通过诱导抗酶移码加速ODC的降解。5)几种氨基酸或碱性氨基酸影响抗酶移码诱导的效率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
J.Satriano: "Agmatine suppresses proliferation by frameshift induction of antizyme and attenuation of cellular polyamine levels." J.Biol.Chem.273-25. 15313-15316 (1998)
J.Satriano:“胍丁胺通过抗酶的移码诱导和细胞多胺水平的减弱来抑制增殖。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
K.Koguchi: "Cloning and sequencing of a human cDNA encoding ornithine decarboxylase antizyme inhibitor." Biochim.Biphys.Acta. 1353.3. 209-216 (1997)
K.Koguchi:“编码鸟氨酸脱羧酶抗酶抑制剂的人类 cDNA 的克隆和测序。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
K.Koguchi: "Cloning and sequencing of a human cDNA encoding ornithine decaboxylase antizyme inhibitor" Biochim.Biophys.Acta. 1353・3. 209-216 (1997)
K.Koguchi:“编码鸟氨酸脱羧酶抗酶抑制剂的人 cDNA 的克隆和测序”Biochim.Biophys.Acta 1353·3(1997)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
T.Nakatani: "Restricted availability affects the antizyme-dependent ODC degradation pathway in isolated primary cultured rat hepatocytes" Biochem.Biophys.Res.Commun.in press.(in press). (1998)
T.Nakatani:“限制可用性会影响分离的原代培养大鼠肝细胞中抗酶依赖性 ODC 降解途径”Biochem.Biophys.Res.Commun.in press(正在出版)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
T.Nakatani: "Restricted Zn^<2+> availability affects the antizyme-dependent ODC degradation pathway inprimarycultured hepatocytes." Biochem. Biophys. Res.Commun.243. 797-800 (1998)
T.Nakatani:“限制 Zn^2 的可用性会影响原代培养的肝细胞中抗酶依赖性 ODC 降解途径。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MURAKAMI Yasuko其他文献

MURAKAMI Yasuko的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MURAKAMI Yasuko', 18)}}的其他基金

Developing a musical instrument activity program in elementary education
制定基础教育中的乐器活动计划
  • 批准号:
    16K04707
  • 财政年份:
    2016
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Effect of n-3 fatty acids supplementation on hepatic phospholipid metabolism in nonalcoholic steatohepatitis.
补充n-3脂肪酸对非酒精性脂肪性肝炎肝磷脂代谢的影响。
  • 批准号:
    24700852
  • 财政年份:
    2012
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Effect of zinc and polyunsaturated fatty acid on chronic hepatitis C.
锌和多不饱和脂肪酸对慢性丙型肝炎的影响。
  • 批准号:
    20700596
  • 财政年份:
    2008
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Antizyme family and their functions
抗酶家族及其功能
  • 批准号:
    11680639
  • 财政年份:
    1999
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanism for degradation of ornithine decarboxylase by 26 S proteasome
26S蛋白酶体降解鸟氨酸脱羧酶的分子机制
  • 批准号:
    05670132
  • 财政年份:
    1993
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似国自然基金

proteasome抑制剂诱导恶性增殖白血病细胞凋亡的分子机制
  • 批准号:
    30100223
  • 批准年份:
    2001
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
Ubiquitin-proteasome系统在多发性肌炎/皮肌炎发病机制中的作用
  • 批准号:
    30170885
  • 批准年份:
    2001
  • 资助金额:
    16.0 万元
  • 项目类别:
    面上项目

相似海外基金

Biosynthesis and bioengineering of epoxyketone proteasome inhibitors
环氧酮蛋白酶体抑制剂的生物合成及生物工程
  • 批准号:
    2590889
  • 财政年份:
    2021
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Studentship
Mechanisms of TGF-β-induced resistance to proteasome inhibitors in multiplemyeloma
TGF-β 诱导多发性骨髓瘤蛋白酶体抑制剂耐药的机制
  • 批准号:
    10532719
  • 财政年份:
    2021
  • 资助金额:
    $ 1.54万
  • 项目类别:
Proteasome inhibitors against mucosal protozoan pathogens
针对粘膜原生动物病原体的蛋白酶体抑制剂
  • 批准号:
    10674897
  • 财政年份:
    2021
  • 资助金额:
    $ 1.54万
  • 项目类别:
Proteasome inhibitors against mucosal protozoan pathogens
针对粘膜原生动物病原体的蛋白酶体抑制剂
  • 批准号:
    10367246
  • 财政年份:
    2021
  • 资助金额:
    $ 1.54万
  • 项目类别:
Mechanisms of TGF-β-induced resistance to proteasome inhibitors in multiplemyeloma
TGF-β 诱导多发性骨髓瘤蛋白酶体抑制剂耐药的机制
  • 批准号:
    10359242
  • 财政年份:
    2021
  • 资助金额:
    $ 1.54万
  • 项目类别:
Macrocyclic proteasome inhibitors for treatment of tuberculosis
用于治疗结核病的大环蛋白酶体抑制剂
  • 批准号:
    9979179
  • 财政年份:
    2020
  • 资助金额:
    $ 1.54万
  • 项目类别:
Discovery of the ubiquitin-proteasome inhibitors from natural sources through cell-based assays
通过基于细胞的检测从天然来源发现泛素蛋白酶体抑制剂
  • 批准号:
    20K16026
  • 财政年份:
    2020
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials
选择性疟原虫蛋白酶体抑制剂作为新型多级抗疟药
  • 批准号:
    10623176
  • 财政年份:
    2019
  • 资助金额:
    $ 1.54万
  • 项目类别:
Development of novel middle-molecule proteasome inhibitors and their drug delivery methods
新型中分子蛋白酶体抑制剂及其给药方法的开发
  • 批准号:
    19K05739
  • 财政年份:
    2019
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials
选择性疟原虫蛋白酶体抑制剂作为新型多级抗疟药
  • 批准号:
    10404078
  • 财政年份:
    2019
  • 资助金额:
    $ 1.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了